Notice2023-02264
Foreign-Trade Zone (FTZ) 46-Cincinnati, Ohio; Notification of Proposed Production Activity; Patheon Pharmaceuticals Inc. (Pharmaceutical Products), Cincinnati, Ohio
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
February 3, 2023
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 23 (Friday, February 3, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 23 (Friday, February 3, 2023)]
[Notices]
[Page 7394]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-02264]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-9-2023]
Foreign-Trade Zone (FTZ) 46--Cincinnati, Ohio; Notification of
Proposed Production Activity; Patheon Pharmaceuticals Inc.
(Pharmaceutical Products), Cincinnati, Ohio
Patheon Pharmaceuticals Inc. (Patheon) submitted a notification of
proposed production activity to the FTZ Board (the Board) for its
facilities in Cincinnati, Ohio, within Subzone 46K. The notification
conforming to the requirements of the Board's regulations (15 CFR
400.22) was received on January 27, 2023.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>.
The proposed finished product is anti-diarrheal drug (active
pharmaceutical ingredient Eluxadoline) packaged into finished dosage
(duty free).
The proposed foreign-status materials and components include active
pharmaceutical ingredient Eluxadoline and mannitol (duty rates, 6.5%
and 4.6%, respectively). The request indicates that the materials/
components are subject to duties under Section 301 of the Trade Act of
1974 (Section 301), depending on the country of origin. The applicable
Section 301 decisions require subject merchandise to be admitted to
FTZs in privileged foreign status (19 CFR 146.41).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#3056444a7044425154551e575f46"><span class="__cf_email__" data-cfemail="c8aebcb288bcbaa9acade6afa7be">[email protected]</span></a>. The closing period for their receipt is March 15, 2023.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Diane Finver at
<a href="/cdn-cgi/l/email-protection#d490bdb5bab1fa92bdbaa2b1a694a0a6b5b0b1fab3bba2"><span class="__cf_email__" data-cfemail="3e7a575f505b10785750485b4c7e4a4c5f5a5b10595148">[email protected]</span></a>.
Dated: January 30, 2023.
Elizabeth Whiteman,
Acting Executive Secretary.
[FR Doc. 2023-02264 Filed 2-2-23; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on February 3, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.